Topoisomerase-IIa as a Predictor of Anthracycline Response

[dlaxague]

That's ANOTHER one of my questions - exactly what you're asking, AA. Although when I try to ask it, most people do not understand what I'm asking.

In the adjuvant Herceptin trials that have reported so far, there doesn't seem to be any additional benefit at all to and anthracycline with Herceptin. But if what we're asking is true, shouldn't we see a small benefit, from that (possibly, if topoIIa is random) 1/6 of those getting Herceptin (who did not benefit from Herceptin but were topoIIa+ and so reaped additional benefit from the anthracycline)? Either that subgroup is too small to affect the larger group's stats, or there's something wrong with the hypothesis - either Slamon's or yours and mine.

Debbie